Prostate Cell News Volume 9.43 | Nov 9 2018

TOP STORY

Structure-Based Assessment and Network Analysis of Targeting 14-3-3 Proteins in Prostate Cancer

Scientists explored whether the small molecule BV02 targeting another 14-3-3 protein family member SFN also binds to YWHAZ. The proteome of metastatic prostate cancer models was perturbed as a result of BV02 treatment. [Mol Cancer] Full Article

(Ranked by impact factor of the journal)

Discovery of ¹⁸F-JK-PSMA-7, a Novel PET-Probe for the Detection of Small PSMA Positive Lesions

Eight novel ¹⁸F-labeled prostate specific membrane antigen (PSMA) ligands were prepared. Their cellular uptake in PSMA⁺ LNCaP C4-2 and PSMA^– PC-3 cells were compared to that of ¹⁸F-DCFPyL. [J Nucl Med] Abstract

MLL3 Enhances the Transcription of PD-L1 and Regulates Anti-Tumor Immunity

Researchers identified histone methyltransferase mixed-lineage leukemia protein 3 (MLL3) as a critical regulator of programmed death-1 ligand 1(PD-L1) in prostate cancer cells. They found that MLL3 bound to the enhancer of PD-L1. Depletion of MLL3 decreased the binding level of H3K4me1 in the enhancer of PD-L1 and Pol II Ser-5p in the promoter of PD-L1. [BBA-Mol Basis Dis] Abstract

Spindle Pole Body Component 25 Regulates Stemness of Prostate Cancer Cells

Compared to spindle pole body component 25 (SPC25)^– cells, SPC25⁺ cells formed significantly more tumor spheres in culture, appeared to be more resistant towards docetaxel-induced cell apoptosis, and generated larger tumors with higher frequency after serial adoptive transplantation. [Aging (Albany NY)] Full Article

Rottlerin Inhibits Cell Growth and Invasion via Down-Regulation of EZH2 in Prostate Cancer

Scientists found that rottlerin treatment led to inhibition of cell growth, migration and invasion, but induction of apoptosis in prostate cancer cells. Overexpression of EZH2 abrogated the rottlerin-induced inhibition of cell growth, migration, and invasion in prostate cancer cells. [Cell Cycle] Abstract

Biological Potential and Mechanism of Prodigiosin from Serratia marcescens Subsp. lawsoniana in Human Choriocarcinoma and Prostate Cancer Cell Lines

The authors explored the anticancer activities and mechanism of strain HDZK-BYSB107 prodigiosin by using human choriocarcinoma (JEG3) and prostate cancer cell lines (PC3) in vitro and JEG3 and PC3 tumor-bearing nude mice in vivo. [Int J Mol Sci] Full Article

Effect of Roasting Levels and Drying Process of Coffea canephora on the Quality of Bioactive Compounds and Cytotoxicity

Investigators showed that extracts from green and light roasted beans exhibited strong bioactive capacity. Coffee extracts promoted a decrease in cell viability, modulated cell cycle and induced apoptosis in a human prostate carcinoma cell line. The level of roasting reduced this property, but the type of drying did not in all cases. [Int J Mol Sci] Full Article

Cell Metabolomics Identify Regulatory Pathways and Targets of Magnoline against Prostate Cancer

Researchers showed that magnoline had a significant inhibitory effect on the proliferation of the prostate cancer cell line 22RV1. They found that 12 metabolic biomarkers of the cell metabolic footprint samples, respectively, could inhibit the proliferation of prostate cancer cells. [J Chromatogr B Analyt Technol Biomed Life Sci] Abstract

Long Noncoding RNA FOXC2-AS1 Facilitates the Proliferation and Progression of Prostate Cancer via Targeting miR-1253/EZH2

The authors revealed that FOXC2-AS1 promoted the proliferation and tumor growth of prostate cancer cells in vitro and in vivo. Mechanically, they found that miR-1253 targeted FOXC2-AS1 at the 3′-untranslated region (UTR), which in turn bound the EZH2 mRNA 3-UTR. [Gene] Abstract | Graphical Abstract

Lysophosphatidic Acid Represses Autophagy in Prostate Carcinoma Cells

Scientists determined that lysophosphatidic acid (LPA) stimulated the ERK and mTOR pathways in complete and serum-free medium. The mTOR pathway led to phosphorylation of S6K and ULK, which respectively stimulated protein synthesis and arrested autophagy. Consistent with this, LPA exposure suppressed autophagy as measured by LC3 maturation and formation of GFP-LC3 puncta. [Biochem Cell Biol] Abstract

Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News.

Circulating Tumor DNA in Advanced Prostate Cancer: Transitioning from Discovery to a Clinically Implemented Test

Several clinical applications have been proposed for circulating cell-free DNA (cfDNA) analysis, including its use as a prognostic tool, as a predictive biomarker, to monitor tumor response and to identify novel mechanisms of resistance. To date, the cfDNA analysis has provided interesting results, but there is an urgent need for these findings to be confirmed in prospective clinical trials. [Prostate Cancer Prostatic Dis] Abstract

Long Non-Coding RNAs in Prostate Cancer: Biological and Clinical Implications

Investigators summarize the biology of long non-coding RNAs and their mechanisms of action in the development and progression of prostate cancer. Additionally, they cast a critical eye over the potential for this class of molecules to impact on clinical practice. [Mol Cell Endocrinol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Sensei Biotherapeutics Presents Clinical Trial Data Demonstrating SNS-301 Induces Rapid and Robust Antigen-Specific Immune Responses

Sensei Biotherapeutics, Inc. announced that clinical and immunological data from the Phase I clinical trial of SNS-301 will be highlighted in a poster presentation. [Press release from Sensei Biotherapeutics. discussing research to be presented at the Society for Immunotherapy of Cancer’s (SITC) 33^rd Annual Meeting, Washington D.C] Press Release

New Clinical Oncology Collaboration between Nektar and Pfizer to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with Avelumab and Talazoparib or Enzalutamide in Multiple Cancers

Nektar Therapeutics announced that it has entered into an oncology clinical collaboration with Pfizer Inc. to evaluate several combination regimens in multiple cancer settings, including metastatic castration-resistant prostate cancer and squamous cell carcinoma of the head and neck. [Nektar] Press Release

OncBioMune Phase II Clinical Trial to Begin Enrollment; Company Announces Other Development and Corporate Milestones

OncBioMune Pharmaceuticals, Inc. provided an update on its upcoming Phase II clinical trials of ProscaVax for prostate cancer and other corporate developments. [OncBioMune Pharmaceuticals, Inc.] Press Release

U.S. Department of Defense Will Finance a New Therapeutic Approach against the Most Aggressive Type of Prostate Cancer

The U.S. Department of Defense has granted the “Impact Award” to explore new therapeutic options against advanced prostate cancer – scientifically known as castration-resistant or hormone therapy resistant prostate cancer- to a multidisciplinary team of researchers. [CNIO] Press Release

BioXcel Therapeutics Announces FDA Acceptance of IND for Lead Immuno-Oncology Candidate, BXCL701, in Treatment Emergent Neuroendocrine Prostate Cancer

BioXcel Therapeutics, Inc. (BTI) announced that the FDA, has accepted its Investigational New Drug (IND) application for its lead immuno-oncology candidate, BXCL701. BTI plans to evaluate BXCL701 in combination with pembrolizumab as a potential therapy for treatment-emergent neuroendocrine prostate cancer. [BioXcel Therapeutics] Press Release

Fortis Therapeutics Receives FDA Clearance of Two IND Applications for Novel Anti-CD46 Therapeutic for Treatment of Late-Stage Prostate Cancer and Multiple Myeloma

Fortis Therapeutics, Inc. announced the FDA has cleared two investigational new drug (IND) applications for the company’s lead candidate, FOR46, for the treatment of metastatic castration-resistant prostate cancer and late-stage multiple myeloma. [Fortis Therapeutics, Inc. (Business Wire, Inc.)] Press Release

Cancer Targeted Technology Files Investigational New Drug Application for CTT1403, a Novel Radiotherapeutic Drug for Prostate Cancer

Cancer Targeted Technology announced that it filed an Investigational New Drug Application with the FDA to move forward a radiotherapeutic drug, CTT1403, into human clinical trials for prostate cancer. CTT1403 is a peptidomimetic drug that targets prostate specific membrane antigen. [Cancer Targeted Technology] Press Release

Sanger Whistle-Blowers Dispute Findings That Cleared Management of Bullying

Current and former employees say investigation at the Wellcome Sanger Institute was flawed; the genomics powerhouse stands by the findings. [Nature News] Editorial

NSF Moves to Pilot LGBT Questions on National Workforce Surveys

Every year, after clicking “submit” on the final copies of their Ph.D. dissertations, thousands of scientists answer all sorts of questions as part of the U.S. National Science Foundation’s (NSF’s) Survey of Earned Doctorates. During a meeting at NSF’s headquarters in Alexandria, the agency said it plans to test the feasibility of adding questions about sexual orientation and gender identity. [ScienceInsider] Editorial

Hospital’s Suspension of Evidence-Based Medicine Expert Sparks New Controversy

The researcher at the center of a controversy roiling Cochrane, an international network of doctors and researchers, headquartered in London, that promotes evidence-based medicine, has been suspended as head of the Nordic Cochrane Centre in Copenhagen. [ScienceInsider] Editorial

NEW Gordon Research Seminar: New Views of Organogenesis and Tumorigenesis: From Single Molecules to Therapeutics
March 23-24, 2019
Ventura, California, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Associate – Molecular and Cell Biology (Baylor College of Medicine)

NEW Postdoctoral Fellow – Advanced Prostate Cancer Research (Cleveland Clinic)

Postdoctoral Fellow/Research Associate Positions – Cell Immortalization (Gerogetown University Medical Center)

Postdoctoral Position – Translational Cancer Research (University of California San Francisco)

Posdoctoral Position – Prostate Cancer Research (Louisiana State University Health Sciences Center)

PhD Studentship – Molecular Radiooncology (German Cancer Research Center)

Group Leader – Cancer Biology and/or Therapy (Institute of Oncology Research Universita della Svizzera Italiana)

PhD Studentships – Cancer Research (The Cancer Research UK Manchester Institute)

Postdoctoral Fellow – Cancer Immunotherapy (University of Notre Dame)

Postdoctoral Fellow – Prostate Disease Research (Henry M. Jackson Foundation for the Advancement of Military Medicine)

Assistant/Associate/Professor – Cancer Biology (University of Cincinnati)

Postdoctoral Position – Prostate Cancer (The University of Minnesota, Twin Cities)

Research Fellow – Prostate Cancer (Sechenov University)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.